Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma

• Sponsor: Children's Oncology Group (Other)
• Overall Status: Completed
• CT.gov ID: NCT00003937
• Collaborator: National Cancer Institute (NCI) (NIH)
• Enrollment: 253
• Locations: 148
• Arms: 3
• Duration (Months): 105
• Patients Per Site: 1.7
• Patients Per Site Per Month: 0

Study Details

Study Description

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemoprotective drugs such as dexrazoxane may protect normal cells from the side effects of chemotherapy.

PURPOSE: Phase III trial to study the effectiveness of three combination chemotherapy regimens plus dexrazoxane in treating patients who have newly diagnosed nonmetastatic osteosarcoma.

Condition or Disease	Intervention/Treatment	Phase
Cardiac Toxicity; Sarcoma	Drug: cisplatin; Drug: dexrazoxane hydrochloride; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate; Procedure: conventional surgery	Phase 3

Detailed Description

OBJECTIVES: I. Compare the efficacy of three intensification regimens (doxorubicin vs doxorubicin plus ifosfamide vs doxorubicin plus ifosfamide and etoposide) in patients with newly diagnosed, previously untreated, nonmetastatic osteosarcoma. II. Determine the effect of postoperative dose intensification on outcome in patients with standard response to preoperative chemotherapy. III. Determine the effect of dexrazoxane cardioprotection during standard induction therapy on histologic response in these patients. IV. Evaluate biological factors that may predict outcome in these patients. V. Determine the safety of dexrazoxane administered with doxorubicin in combination with cisplatin or cisplatin and ifosfamide in these patients. VI. Determine the effect of dexrazoxane on cytotoxicity as measured by tumor necrosis at definitive surgery in these patients. VII. Assess the feasibility of administering doxorubicin with dexrazoxane cardioprotection or high dose ifosfamide with etoposide to standard risk patients who are also receiving methotrexate and cisplatin.

OUTLINE: This is a multicenter study. Patients are enrolled sequentially on 1 of 3 pilot intensification regimens. After surgery to completely remove the primary tumor, patients are assigned to 1 of 2 adjuvant chemotherapy groups based on percent necrosis at limb salvage. Pilot 1: (Closed to accrual as of 6/2/2000) Patients receive dexrazoxane IV followed immediately by doxorubicin IV over 20 minutes plus cisplatin IV over 4 hours on days 1 and 2 of weeks 1 and 6. Methotrexate IV over 4 hours is administered on day 1 of weeks 4, 5, 9, and 10. Patients undergo surgery on week 11. Adjuvant chemotherapy begins on day 1 of week 13. Group 1 (good response to neoadjuvant chemotherapy): Patients receive methotrexate IV over 4 hours every 3 weeks for 6 courses, beginning on week 13. Patients also receive dexrazoxane and doxorubicin every 3 weeks for 4 courses, beginning on week 14. Cisplatin is administered with the first 2 courses of dexrazoxane and doxorubicin. Group 2 (standard response to neoadjuvant chemotherapy): Patients receive methotrexate and cisplatin as in group 1 plus dexrazoxane and doxorubicin for 6 courses. Pilot 2: Patients receive preoperative therapy comprised of dexrazoxane, doxorubicin, and methotrexate as in pilot 1. Ifosfamide IV over 4 hours is also administered on days 1-5 of week 1. Patients undergo surgery on week 11, then begin adjuvant chemotherapy on week 13. Group 1: Patients receive methotrexate, dexrazoxane, and doxorubicin as in pilot 1, group 1. Ifosfamide is also administered on weeks 14 and 20. Cisplatin is administered on weeks 17, 23, and 26. Group 2: Patients receive methotrexate, dexrazoxane, and doxorubicin as in pilot 1, group 2. Ifosfamide is administered on weeks 14, 20, 26, and 31. Cisplatin is administered on weeks 17, 23, and 29. Pilot 3: (Open to accrual as of 6/2/2000) Patients receive preoperative therapy comprised of methotrexate, dexrazoxane, doxorubicin, ifosfamide, and cisplatin as in pilot 2. Patients undergo surgery on week 11, then begin adjuvant chemotherapy on week 13. Group 1: Patients receive methotrexate, dexrazoxane, doxorubicin, ifosfamide, and cisplatin as in pilot 2, group 1. Group 2: Patients receive methotrexate on weeks 13, 19, 29, 32, 35, and 36, high dose ifosfamide and etoposide IV over 4 hours on days 1-5 of weeks 14, 23, and 26, and cisplatin on weeks 20, 30, and 33. Dexrazoxane and doxorubicin are administered on weeks 17, 20, 30, and 33. Patients are followed every 3 months for 1 year, every 6 months for 4 years and then annually thereafter.

PROJECTED ACCRUAL: Approximately 180 patients will be accrued for this study within 2 years.

Study Design

• Study Type: Interventional
• Actual Enrollment: 253 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Protocol for Patients With Newly-Diagnosed Non-Metastatic Osteosarcoma - A POG/CCG Pilot Intergroup Study
• Study Start Date: Sep 1, 1999
• Actual Primary Completion Date: Mar 1, 2004
• Actual Study Completion Date: Jun 1, 2008

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Pilot 1 - Doxorubicin Intensification without Ifosfamide Dexrazoxane hydrochloride IV followed by doxorubicin hydrochloride IV plus cisplatin IV on days 1 and 2 of weeks 1 and 6. Methotrexate IV on day 1 of weeks 4, 5, 9, and 10. Patients undergo surgery on week 11. Adjuvant chemotherapy begins on day 1 of week 13. Group 1 (good response to neoadjuvant chemotherapy): Patients receive methotrexate IV over 4 hours every 3 weeks for 6 courses, beginning on week 13. Patients also receive dexrazoxane and doxorubicin hydrochloride every 3 weeks for 4 courses, beginning on week 14. Cisplatin is administered with the first 2 courses of dexrazoxane and doxorubicin. Group 2 (standard response to neoadjuvant chemotherapy): Patients receive methotrexate and cisplatin as in group 1 plus dexrazoxane and doxorubicin hydrochloride for 6 courses.	Drug: cisplatin; Other Names: Cis-diamminedichloroplatinum II CDDP Platinol NSC #119875 ; Drug: dexrazoxane hydrochloride; Other Names: ADR-529 ZINECARD ICRF-187 NSC #169780 ; Drug: doxorubicin hydrochloride; Other Names: Adriamycin NSC #123127 ; Drug: methotrexate; Other Names: MTX amethopterin NSC #000740 ; Procedure: conventional surgery
Experimental: Pilot 2 - Doxorubicin Intensification with Ifosfamide Preoperative therapy comprised of dexrazoxane hydrochloride, doxorubicin hydrochloride, and methotrexate as in pilot 1. Ifosfamide IV on days 1-5 of week 1. Patients undergo surgery on week 11, then begin adjuvant chemotherapy on week 13. Group 1: Patients receive methotrexate, dexrazoxane hydrochloride, and doxorubicin hydrochloride as in pilot 1, group 1. Ifosfamide is also administered on weeks 14 and 20. Cisplatin is administered on weeks 17, 23, and 26. Group 2: Patients receive methotrexate, dexrazoxane hydrochloride, and doxorubicin hydrochloride as in pilot 1, group 2. Ifosfamide is administered on weeks 14, 20, 26, and 31. Cisplatin is administered on weeks 17, 23, and 29	Drug: cisplatin; Other Names: Cis-diamminedichloroplatinum II CDDP Platinol NSC #119875 ; Drug: dexrazoxane hydrochloride; Other Names: ADR-529 ZINECARD ICRF-187 NSC #169780 ; Drug: doxorubicin hydrochloride; Other Names: Adriamycin NSC #123127 ; Drug: ifosfamide; Other Names: IFX IFOS NSC #109724 ; Drug: methotrexate; Other Names: MTX amethopterin NSC #000740 ; Procedure: conventional surgery
Experimental: Pilot 3 - Ifosfamide/Etoposide Intensification Preoperative therapy comprised of methotrexate, dexrazoxane hydrochloride, doxorubicin, ifosfamide, and cisplatin as in pilot 2. Patients undergo surgery on week 11, then begin adjuvant chemotherapy on week 13. Group 1: Patients receive methotrexate, dexrazoxane hydrochloride, doxorubicin, ifosfamide, and cisplatin as in pilot 2, group 1. Group 2: Patients receive methotrexate on weeks 13, 19, 29, 32, 35, and 36, high dose ifosfamide and etoposide IV over 4 hours on days 1-5 of weeks 14, 23, and 26, and cisplatin on weeks 20, 30, and 33. Dexrazoxane hydrochloride and doxorubicin hydrochloride are administered on weeks 17, 20, 30, and 33	Drug: cisplatin; Other Names: Cis-diamminedichloroplatinum II CDDP Platinol NSC #119875 ; Drug: dexrazoxane hydrochloride; Other Names: ADR-529 ZINECARD ICRF-187 NSC #169780 ; Drug: doxorubicin hydrochloride; Other Names: Adriamycin NSC #123127 ; Drug: etoposide; Other Names: VP-16 VePesid NSC #141540 ; Drug: ifosfamide; Other Names: IFX IFOS NSC #109724 ; Drug: methotrexate; Other Names: MTX amethopterin NSC #000740 ; Procedure: conventional surgery

Outcome Measures

Primary Outcome Measures

1. Event Free Survival []

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A to 30 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

DISEASE CHARACTERISTICS: Histologically proven newly diagnosed moderate or high grade osteosarcoma without metastases No prior treatment, including complete resection No parosteal or periosteal sarcoma No osteosarcoma associated with Paget's disease No nonresectable tumors or tumors that may result in marginal or interlesion resection Must be enrolled on protocol POG-9851

PATIENT CHARACTERISTICS: Age: 30 and under Performance status: ECOG 0-2 Life expectancy:

Not specified Hematopoietic: Absolute neutrophil count at least 1,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times normal SGOT no greater than 3 times normal Renal: Creatinine normal Phosphate at least 3.0 mg/dL without supplementation Cardiovascular: Shortening fraction at least 28% by echocardiogram If echocardiogram unsatisfactory, must have ejection fraction at least 50% No history of pericarditis or myocarditis No symptomatic arrhythmia or symptomatic cardiac conduction disturbances

PRIOR CONCURRENT THERAPY: See Disease Characteristics Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery: See Disease Characteristics

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Alabama at Birmingham Comprehensive Cancer Center	Birmingham	Alabama	United States	35294-3300
2	MBCCOP - Gulf Coast	Mobile	Alabama	United States	36688
3	Arizona Cancer Center	Tucson	Arizona	United States	85724
4	University of Arkansas for Medical Sciences	Little Rock	Arkansas	United States	72205
5	University of California San Diego Cancer Center	La Jolla	California	United States	92093-0658
6	Long Beach Memorial Medical Center	Long Beach	California	United States	90806
7	Children's Hospital Los Angeles	Los Angeles	California	United States	90027-0700
8	Jonsson Comprehensive Cancer Center, UCLA	Los Angeles	California	United States	90095-1781
9	Children's Hospital of Orange County	Orange	California	United States	92868
10	Lucile Packard Children's Hospital at Stanford	Palo Alto	California	United States	94304
11	Sutter Cancer Center	Sacramento	California	United States	95816
12	University of California Davis Medical Center	Sacramento	California	United States	95817
13	Kaiser Permanente-Southern California Permanente Medical Group	San Diego	California	United States	92120
14	Children's Hospital and Health Center	San Diego	California	United States	92123-4282
15	UCSF Cancer Center and Cancer Research Institute	San Francisco	California	United States	94143-0128
16	Kaiser Permanente Medical Center - Santa Clara	Santa Clara	California	United States	95051-5386
17	David Grant Medical Center	Travis Air Force Base	California	United States	94535
18	Children's Hospital of Denver	Denver	Colorado	United States	80218
19	Yale Comprehensive Cancer Center	New Haven	Connecticut	United States	06520-8028
20	Children's National Medical Center	Washington	District of Columbia	United States	20010-2970
21	Walter Reed Army Medical Center	Washington	District of Columbia	United States	20307-5000
22	Shands Hospital and Clinics, University of Florida	Gainesville	Florida	United States	32610-100277
23	Nemours Children's Clinic	Jacksonville	Florida	United States	32207
24	Sylvester Cancer Center, University of Miami	Miami	Florida	United States	33136
25	Miami Children's Hospital	Miami	Florida	United States	33155
26	Baptist Hospital of Miami	Miami	Florida	United States	33176-2197
27	Walt Disney Memorial Cancer Institute	Orlando	Florida	United States	32803
28	All Children's Hospital	St. Petersburg	Florida	United States	33701
29	CCOP - Florida Pediatric	Tampa	Florida	United States	33682-7757
30	St. Mary's Hospital	West Palm Beach	Florida	United States	33407
31	Emory University Hospital - Atlanta	Atlanta	Georgia	United States	30322
32	Cancer Research Center of Hawaii	Honolulu	Hawaii	United States	96813
33	Tripler Army Medical Center	Honolulu	Hawaii	United States	96859-5000
34	Rush-Presbyterian-St. Luke's Medical Center	Chicago	Illinois	United States	60612
35	Children's Memorial Hospital, Chicago	Chicago	Illinois	United States	60614
36	University of Chicago Cancer Research Center	Chicago	Illinois	United States	60637-1470
37	Hope Children's Hospital	Oak Lawn	Illinois	United States	60453
38	CCOP - Illinois Oncology Research Association	Peoria	Illinois	United States	61602
39	Saint Jude Midwest Affiliate	Peoria	Illinois	United States	61637
40	Indiana University Cancer Center	Indianapolis	Indiana	United States	46202-5289
41	Holden Comprehensive Cancer Center at The University of Iowa	Iowa City	Iowa	United States	52242-1009
42	University of Kansas Medical Center	Kansas City	Kansas	United States	66160-7357
43	CCOP - Wichita	Wichita	Kansas	United States	67214-3882
44	Via Christi Regional Medical Center	Wichita	Kansas	United States	67214
45	MBCCOP - LSU Health Sciences Center	New Orleans	Louisiana	United States	70112
46	Tulane University School of Medicine	New Orleans	Louisiana	United States	70112
47	CCOP - Ochsner	New Orleans	Louisiana	United States	70121
48	Eastern Maine Medical Center	Bangor	Maine	United States	04401
49	Maine Children's Cancer Program	Portland	Maine	United States	04101
50	Marlene & Stewart Greenebaum Cancer Center, University of Maryland	Baltimore	Maryland	United States	21201
51	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Baltimore	Maryland	United States	21231-2410
52	Boston Floating Hospital Infants and Children	Boston	Massachusetts	United States	02111
53	Massachusetts General Hospital Cancer Center	Boston	Massachusetts	United States	02114
54	Dana-Farber Cancer Institute	Boston	Massachusetts	United States	02115
55	University of Massachusetts Memorial Medical Center	Worcester	Massachusetts	United States	01655
56	University of Michigan Comprehensive Cancer Center	Ann Arbor	Michigan	United States	48109-0752
57	Children's Hospital of Michigan	Detroit	Michigan	United States	48201
58	St. John's Hospital and Medical Center	Detroit	Michigan	United States	48236
59	Hurley Medical Center	Flint	Michigan	United States	48503
60	CCOP - Kalamazoo	Kalamazoo	Michigan	United States	49007-3731
61	University of Minnesota Cancer Center	Minneapolis	Minnesota	United States	55455
62	Mayo Clinic Cancer Center	Rochester	Minnesota	United States	55905
63	University of Mississippi Medical Center	Jackson	Mississippi	United States	39216-4505
64	Keesler Medical Center - Keesler AFB	Keesler AFB	Mississippi	United States	39534-2576
65	University of Missouri-Columbia Hospital and Clinics	Columbia	Missouri	United States	65212
66	Children's Mercy Hospital	Kansas City	Missouri	United States	64108
67	Cardinal Glennon Children's Hospital	Saint Louis	Missouri	United States	63104
68	Washington University School of Medicine	Saint Louis	Missouri	United States	63110
69	University of Nebraska Medical Center	Omaha	Nebraska	United States	68198-3330
70	Norris Cotton Cancer Center	Lebanon	New Hampshire	United States	03756-0002
71	CCOP - Northern New Jersey	Hackensack	New Jersey	United States	07601
72	Hackensack University Medical Center	Hackensack	New Jersey	United States	07601
73	Cancer Institute of New Jersey	New Brunswick	New Jersey	United States	08901
74	University of New Mexico School of Medicine	Albuquerque	New Mexico	United States	87131
75	Roswell Park Cancer Institute	Buffalo	New York	United States	14263-0001
76	Schneider Children's Hospital	New Hyde Park	New York	United States	11042
77	NYU School of Medicine's Kaplan Comprehensive Cancer Center	New York	New York	United States	10016
78	Memorial Sloan-Kettering Cancer Center	New York	New York	United States	10021
79	Mount Sinai School of Medicine	New York	New York	United States	10029
80	Herbert Irving Comprehensive Cancer Center	New York	New York	United States	10032
81	University of Rochester Cancer Center	Rochester	New York	United States	14642
82	State University of New York Health Sciences Center - Stony Brook	Stony Brook	New York	United States	11790-7775
83	State University of New York - Upstate Medical University	Syracuse	New York	United States	13210
84	Mission Saint Joseph's Health System	Asheville	North Carolina	United States	28801
85	Lineberger Comprehensive Cancer Center, UNC	Chapel Hill	North Carolina	United States	27599-7295
86	Carolinas Medical Center	Charlotte	North Carolina	United States	28232-2861
87	Presbyterian Healthcare	Charlotte	North Carolina	United States	28233-3549
88	Duke Comprehensive Cancer Center	Durham	North Carolina	United States	27710
89	East Carolina University School of Medicine	Greenville	North Carolina	United States	27858-4354
90	Comprehensive Cancer Center at Wake Forest University	Winston-Salem	North Carolina	United States	27157-1082
91	Veterans Affairs Medical Center - Fargo	Fargo	North Dakota	United States	58102
92	CCOP - Merit Care Hospital	Fargo	North Dakota	United States	58122
93	Children's Hospital Medical Center - Cincinnati	Cincinnati	Ohio	United States	45229-3039
94	Ireland Cancer Center	Cleveland	Ohio	United States	44106-5065
95	Children's Hospital of Columbus	Columbus	Ohio	United States	43205-2696
96	Oklahoma Memorial Hospital	Oklahoma City	Oklahoma	United States	73126-0307
97	Natalie Warren Bryant Cancer Center	Tulsa	Oklahoma	United States	74136
98	Doernbecher Children's Hospital	Portland	Oregon	United States	97201-3098
99	CCOP - Columbia River Program	Portland	Oregon	United States	97213
100	Legacy Emanuel Hospital and Health Center	Portland	Oregon	United States	97227
101	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania	United States	19104
102	St. Christopher's Hospital for Children	Philadelphia	Pennsylvania	United States	19134-1095
103	Children's Hospital of Pittsburgh	Pittsburgh	Pennsylvania	United States	15213
104	Medical University of South Carolina	Charleston	South Carolina	United States	29425-0721
105	Children's Hospital of Greenville Hospital System	Greenville	South Carolina	United States	29605
106	James H. Quillen College of Medicine	Johnson City	Tennessee	United States	37614-0622
107	Saint Jude Children's Research Hospital	Memphis	Tennessee	United States	38105-2794
108	Vanderbilt-Ingram Cancer Center	Nashville	Tennessee	United States	37232-6838
109	Texas Oncology P.A.	Dallas	Texas	United States	75230-2503
110	Medical City Dallas Hospital	Dallas	Texas	United States	75230
111	Simmons Cancer Center - Dallas	Dallas	Texas	United States	75235-9154
112	University of Texas Medical Branch	Galveston	Texas	United States	77555-0209
113	University of Texas - MD Anderson Cancer Center	Houston	Texas	United States	77030-4009
114	Baylor College of Medicine	Houston	Texas	United States	77030
115	San Antonio Military Pediatric Cancer and Blood Disorders Center	Lackland Air Force Base	Texas	United States	78236-5300
116	MBCCOP - South Texas Pediatric	San Antonio	Texas	United States	78229-3900
117	University of Texas Health Science Center at San Antonio	San Antonio	Texas	United States	78284-7811
118	Scott and White Clinic	Temple	Texas	United States	76508
119	Vermont Cancer Center	Burlington	Vermont	United States	05401-3498
120	Cancer Center at the University of Virginia	Charlottesville	Virginia	United States	22908
121	Inova Fairfax Hospital	Falls Church	Virginia	United States	22042-3300
122	Naval Medical Center, Portsmouth	Portsmouth	Virginia	United States	23708-2197
123	Massey Cancer Center	Richmond	Virginia	United States	23298-0037
124	Carilion Roanoke Community Hospital	Roanoke	Virginia	United States	24029
125	Children's Hospital and Regional Medical Center - Seattle	Seattle	Washington	United States	98105
126	Fred Hutchinson Cancer Research Center	Seattle	Washington	United States	98109-1024
127	Madigan Army Medical Center	Tacoma	Washington	United States	98431-5000
128	West Virginia University Medical School-Charleston	Charleston	West Virginia	United States	25304
129	West Virginia University Hospitals	Morgantown	West Virginia	United States	26506-9300
130	St. Vincent Hospital	Green Bay	Wisconsin	United States	54307-3508
131	University of Wisconsin Comprehensive Cancer Center	Madison	Wisconsin	United States	53792-6164
132	Midwest Children's Cancer Center	Milwaukee	Wisconsin	United States	53226
133	Royal Children's Hospital	Parkville	Victoria	Australia	3052
134	Princess Margaret Hospital for Children	Perth	Western Australia	Australia	6001
135	Alberta Children's Hospital	Calgary	Alberta	Canada	T2T 5C7
136	Cross Cancer Institute	Edmonton	Alberta	Canada	T6G 1Z2
137	British Columbia Children's Hospital	Vancouver	British Columbia	Canada	V6H 3V4
138	IWK Health Centre	Halifax	Nova Scotia	Canada	B3J 3G9
139	Children's Hospital	Hamilton	Ontario	Canada	L8N 3Z5
140	Children's Hospital of Eastern Ontario	Ottawa	Ontario	Canada	K1H 8L1
141	Hospital for Sick Children	Toronto	Ontario	Canada	M5G 1X8
142	McGill University Health Center - Montreal Children's Hospital	Montreal	Quebec	Canada	H3H 1P3
143	Hopital Sainte Justine	Montreal	Quebec	Canada	H3T 1C5
144	Centre Hospitalier de L'Universite Laval	Sainte Foy	Quebec	Canada	GIV 4G2
145	Academisch Ziekenhuis Groningen	Groningen		Netherlands	9713 EZ
146	San Jorge Childrens Hospital	Santurce		Puerto Rico	00912
147	Swiss Pediatric Oncology Group Bern	Bern		Switzerland	CH 3010
148	Clinique de Pediatrie	Geneva		Switzerland	1211

Sponsors and Collaborators

• Children's Oncology Group
• National Cancer Institute (NCI)

Investigators

• Study Chair: Cindy Schwartz, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study Documents (Full-Text)

None provided.

More Information

Publications

• Isakoff MS, Barkauskas DA, Ebb D, Morris C, Letson GD. Poor survival for osteosarcoma of the pelvis: a report from the Children's Oncology Group. Clin Orthop Relat Res. 2012 Jul;470(7):2007-13. doi: 10.1007/s11999-012-2284-9. Epub 2012 Feb 22.
• Janeway KA, Barkauskas DA, Krailo MD, Meyers PA, Schwartz CL, Ebb DH, Seibel NL, Grier HE, Gorlick R, Marina N. Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group. Cancer. 2012 Sep 15;118(18):4597-605. doi: 10.1002/cncr.27414. Epub 2012 Jan 17.

• Responsible Party: Children's Oncology Group
• ClinicalTrials.gov Identifier: NCT00003937
• Other Study ID Numbers: P9754; COG-P9754; POG-P9754; CCG-P9754; CDR0000067129
• First Posted: Feb 9, 2004
• Last Update Posted: Aug 5, 2014
• Last Verified: Aug 1, 2014

• Keywords provided by Children's Oncology Group: localized osteosarcoma; cardiac toxicity
• Additional relevant MeSH terms: Osteosarcoma; Cardiotoxicity; Cisplatin; Doxorubicin; Liposomal doxorubicin; Methotrexate; Etoposide; Ifosfamide; Dexrazoxane; Razoxane

Study Results

No Results Posted as of Aug 5, 2014